Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Keith, Nancy
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma	Active, not recruiting	2	95	US	safusidenib, DS-1001b, AB-218	Nuvation Bio Inc., AnHeart Therapeutics Inc.	Glioma	03/27	07/27